[go: up one dir, main page]

NO20076319L - Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav - Google Patents

Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav

Info

Publication number
NO20076319L
NO20076319L NO20076319A NO20076319A NO20076319L NO 20076319 L NO20076319 L NO 20076319L NO 20076319 A NO20076319 A NO 20076319A NO 20076319 A NO20076319 A NO 20076319A NO 20076319 L NO20076319 L NO 20076319L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
neuroactive steroid
regnan
methoxymethyl
imidazolyl
Prior art date
Application number
NO20076319A
Other languages
English (en)
Norwegian (no)
Inventor
Richard M Woodward
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of NO20076319L publication Critical patent/NO20076319L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20076319A 2005-06-09 2007-12-07 Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav NO20076319L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68890505P 2005-06-09 2005-06-09
PCT/EP2006/005574 WO2006131392A1 (fr) 2005-06-09 2006-06-09 Compositions pharmaceutiques a base d'un steroide neuroactif et leurs utilisations

Publications (1)

Publication Number Publication Date
NO20076319L true NO20076319L (no) 2007-12-07

Family

ID=36790861

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076319A NO20076319L (no) 2005-06-09 2007-12-07 Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav

Country Status (25)

Country Link
US (2) US20090131383A1 (fr)
EP (3) EP2168585B1 (fr)
JP (2) JP2008542419A (fr)
KR (3) KR20120028407A (fr)
CN (1) CN101193640A (fr)
AT (2) ATE538797T1 (fr)
AU (1) AU2006256851C1 (fr)
BR (1) BRPI0612921A2 (fr)
CA (1) CA2611430C (fr)
CY (2) CY1110199T1 (fr)
DE (1) DE602006013622D1 (fr)
DK (2) DK1888080T3 (fr)
EA (1) EA013744B1 (fr)
ES (2) ES2380060T3 (fr)
HR (2) HRP20100372T1 (fr)
IL (3) IL187813A (fr)
NO (1) NO20076319L (fr)
NZ (1) NZ562979A (fr)
PL (2) PL1888080T3 (fr)
PT (2) PT2168585E (fr)
RS (2) RS51304B (fr)
SI (2) SI2168585T1 (fr)
UA (1) UA94909C2 (fr)
WO (1) WO2006131392A1 (fr)
ZA (1) ZA200709188B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113234114A (zh) 2011-10-14 2021-08-10 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
WO2014169836A1 (fr) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor-stéroïdes neuroactifs et procédés d'utilisation de ceux-ci
WO2014169831A1 (fr) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor-hétéroaryl-stéroïdes c21-c-liés c3,3-disubstitués et procédés d'utilisation de ceux-ci
WO2014169832A1 (fr) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. Stéroïdes neuroactifs 19-nor et procédés d'utilisation de ceux-ci
MX362543B (es) 2013-04-17 2019-01-24 Sage Therapeutics Inc Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos.
HRP20210610T1 (hr) 2013-07-19 2021-05-28 Sage Therapeutics, Inc. Neuroaktivni steroidi, pripravci i njihove uporabe
PT3035940T (pt) 2013-08-23 2019-01-28 Sage Therapeutics Inc Esteroides neuroativos, composições e seus usos
WO2015195962A1 (fr) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Stéroïdes neuroactifs, leurs compositions et utilisations
EP3885352B1 (fr) * 2014-10-16 2024-11-27 Sage Therapeutics, Inc. Un composé, ses compositions et ce composé pour le traitement de troubles du système nerveux central
EP4275748A3 (fr) 2014-10-16 2024-01-03 Sage Therapeutics, Inc. Compositions et méthodes pour traiter des troubles du snc
RS60343B1 (sr) 2014-11-27 2020-07-31 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
SMT202100113T1 (it) 2015-01-26 2021-05-07 Sage Therapeutics Inc Composizioni e metodi per trattare disturbi del snc
EP3258939B1 (fr) 2015-02-20 2022-09-07 Sage Therapeutics, Inc. Stéroïdes neuroactifs, compositions, et leurs utilisations
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
AU2017296295B2 (en) 2016-07-11 2022-02-24 Sage Therapeutics, Inc. C7, C12, and C16 substituted neuroactive steroids and their methods of use
EP3678670A1 (fr) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Stéroïdes neuroactifs et leurs méthodes d'utilisation
US10562930B1 (en) * 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
KR20210149028A (ko) * 2018-12-14 2021-12-08 프락시스 프리시젼 메디신즈, 인크. 우울증의 치료 방법
KR20210105934A (ko) * 2018-12-17 2021-08-27 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
EP3934655A4 (fr) * 2019-03-04 2022-12-21 Praxis Precision Medicines, Inc. Méthodes de traitement de la périménopause et de la ménopause
AR119047A1 (es) 2019-05-31 2021-11-17 Sage Therapeutics Inc Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc
MX2022004022A (es) * 2019-10-02 2022-05-18 Praxis Prec Medicines Inc Combinaciones de moduladores alostericos positivos del receptor de gaba-a y antagonistas de nmda, moduladores alostericos negativos de nmda o agonistas parciales de nmda.
WO2021168106A1 (fr) * 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Neurostéroïde deutéré
US20240148756A1 (en) 2021-02-18 2024-05-09 Sage Therapeutics, Inc. Use of neuroactive steroid for treatment of sexual dysfunction
EP4294819A4 (fr) 2021-02-18 2024-12-18 Praxis Precision Medicines, Inc. Sels d'hémi-citrate de modulateur allostérique positif de gaba-a et forme cristalline correspondantes
TW202308653A (zh) * 2021-04-26 2023-03-01 美商普雷西斯精密藥品股份有限公司 以神經活性類固醇進行治療的方法
WO2023159035A1 (fr) 2022-02-16 2023-08-24 Sage Therapeutics, Inc. Stéroïdes neuroactifs pour le traitement de troubles liés au snc
WO2023159094A2 (fr) * 2022-02-16 2023-08-24 Praxis Precision Medicines, Inc. PROCEDE DE FABRICATION DE 3α-HYDROXY-3β-MÉTHOXYMÉTHYL-21-(1'-IMIDAZOLYL)-5α-PRÉGNAN-20-ONE
WO2023164386A1 (fr) 2022-02-28 2023-08-31 Sage Therapeutics, Inc. Stéroïdes neuroactifs pour le traitement de maladies ou d'états gastro-intestinaux
JP2024115533A (ja) * 2023-02-14 2024-08-26 沢井製薬株式会社 コーティング顆粒、コーティング顆粒を含む製剤及びそれらの製造方法
WO2025059464A1 (fr) * 2023-09-15 2025-03-20 Praxis Precision Medicines, Inc. Détermination de l'effet d'un médicament sur la base de l'activité cérébrale et d'un modèle d'apprentissage automatique entraîné

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2535202B1 (fr) * 1982-11-03 1985-08-09 Fabre Sa Pierre Comprimes de theophylline a liberation controlee et leur procede de fabrication
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4884909A (en) 1986-12-25 1989-12-05 Canon Kabushiki Kaisha Recording apparatus
DK1038880T3 (da) * 1994-02-14 2008-03-03 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US7083808B2 (en) * 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
HUP0201818A3 (en) * 1999-04-29 2004-04-28 Euro Celtique Sa 3alpha-hydroxy-3beta-methoxymethyl-21-heterocycle substituted steroids with anesthetic activity and pharmaceutical compositions containing the same
US6387403B1 (en) * 1999-09-15 2002-05-14 Alza Corporation Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
US6080736A (en) * 1999-10-27 2000-06-27 Janus Pharmaceuticals, Inc. Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
GB0218876D0 (en) * 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
US20060074059A1 (en) * 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one

Also Published As

Publication number Publication date
CN101193640A (zh) 2008-06-04
CA2611430C (fr) 2013-09-10
IL216194A (en) 2013-09-30
DE602006013622D1 (de) 2010-05-27
HRP20120264T1 (hr) 2012-04-30
ES2344313T3 (es) 2010-08-24
HK1140947A1 (en) 2010-10-29
EP1888080A1 (fr) 2008-02-20
EA200800007A1 (ru) 2008-04-28
WO2006131392A1 (fr) 2006-12-14
EA013744B1 (ru) 2010-06-30
JP2008542419A (ja) 2008-11-27
CY1112499T1 (el) 2015-12-09
DK1888080T3 (da) 2010-07-19
AU2006256851C1 (en) 2010-07-15
EP1888080B1 (fr) 2010-04-14
IL187813A (en) 2011-12-29
KR20120028407A (ko) 2012-03-22
SI1888080T1 (sl) 2010-08-31
PT2168585E (pt) 2012-03-05
EP2263675A3 (fr) 2011-05-18
HRP20100372T1 (hr) 2010-08-31
JP2012229261A (ja) 2012-11-22
US20120276196A1 (en) 2012-11-01
IL187813A0 (en) 2008-08-07
HK1118202A1 (en) 2009-02-06
SI2168585T1 (sl) 2012-04-30
WO2006131392A8 (fr) 2007-02-15
PL1888080T3 (pl) 2010-09-30
ATE464054T1 (de) 2010-04-15
IL211114A (en) 2014-04-30
ES2380060T3 (es) 2012-05-08
EP2168585A1 (fr) 2010-03-31
CA2611430A1 (fr) 2006-12-14
NZ562979A (en) 2010-11-26
CY1110199T1 (el) 2015-01-14
EP2168585B1 (fr) 2011-12-28
ATE538797T1 (de) 2012-01-15
EP2263675A2 (fr) 2010-12-22
US20090131383A1 (en) 2009-05-21
AU2006256851A1 (en) 2006-12-14
AU2006256851B2 (en) 2009-12-17
BRPI0612921A2 (pt) 2010-12-07
DK2168585T3 (da) 2012-02-27
KR20080017091A (ko) 2008-02-25
RS51304B (sr) 2010-12-31
KR20100095661A (ko) 2010-08-31
IL216194A0 (en) 2012-01-31
PT1888080E (pt) 2010-07-06
PL2168585T3 (pl) 2012-05-31
RS52199B (sr) 2012-10-31
ZA200709188B (en) 2008-08-27
UA94909C2 (ru) 2011-06-25

Similar Documents

Publication Publication Date Title
NO20076319L (no) Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
NO20092723L (no) Indazolylester og amidderivater for behandling av gluccocorticoid reseptormedierte sykdommer
TW200607807A (en) Macrocyclic beta-secretase inhibitors
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
TW200837074A (en) Extended triterpene derivatives
NO20074441L (no) 1-benzylindol-2-karboksamidderivater
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
NO20071058L (no) Risedronatsammensetninger og deres fremgangsmater for anvendelse
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
NO20090664L (no) Purinderivater som A2A-agonister
NO20076357L (no) Azabicykliske heterocykler som cannabinoid reseptor modulatorer
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
ATE490958T1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
NO20061702L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en ostrogen agonist/antagonist
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister
BR0105787A (pt) Composição farmacêutica, uso de um composto farmacêutico, método para tratamento de distúrbios, composto farmacêutico e método para confeccionar um composto farmacêutico
NO20056218L (no) Substituerte pyrrolderivater og anvendelse derav som HMF-CoA reduktase-inhibitorer
DK1784173T3 (da) Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater
WO2006036981A3 (fr) Petits modulateurs moleculaires de l'activite de cytokines
TW200732304A (en) Piperidine derivatives
NO20065551L (no) Anvendelse av opoid reseptor antagonistforbindelser for forhindring og/eller behandling av sykdommer assosiert med malet calcineurin
NZ588470A (en) Pharmaceutical composition comprising a benzophenone derivative and an immunosuppressing agent for treating autoimmune diseases

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: EURO-CELTIQUE SA, LU

FC2A Withdrawal, rejection or dismissal of laid open patent application